Apex Capital’s GSK GSK Stock Holding History

Apex Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$28.2M	Buy	560,080 +120,080	+27%	+$6.12M	3.01%	12
2015 Q3	$21.1M	Buy	+440,000	New	+$22.9M	2.01%	20

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Apex Capital's GSK Position: Q4 2015 in Review

Apex Capital increased its GSK (GSK) stake by 27% in Q4 2015, buying an estimated $6.12M and bringing the position to 560,080 shares worth $28.2M. The position accounts for 3.01% of the portfolio, ranked #12.

Apex Capital first reported a position in GSK in Q3 2015 and has held it in 2 quarters since. 719 funds tracked by Wall St. Rank hold GSK as of Q4 2015.

Apex Capital held 560,080 shares of GSK worth $28.2M as of Q4 2015.
Apex Capital bought 120,080 GSK shares in Q4 2015, an estimated $6.12M.
GSK made up 3.01% of Apex Capital's portfolio in Q4 2015, its #12 holding.
Apex Capital first reported a position in GSK in Q3 2015 and has held it in 2 quarters since.
719 funds tracked by Wall St. Rank held GSK as of Q4 2015.

Based on Apex Capital's 13F filing for Q4 2015, filed 16 Feb 2016.